However, they did not suggest using KRT7 mRNA for monitoring the therapeutic response to the chemotherapeutic drugs or survival rate in patients with advanced lung cancer because CTCs appeared to be significantly more resistant to chemotherapeutic drugs than non-metastatic tumor cells. This evidence concerns the gene KRT7 and neoplasm.